Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | XB371 |
| Synonyms | |
| Therapy Description |
XB371 is an antibody-drug conjugate (ADC) comprising a monoclonal antibody targeting tissue factor (TF) linked to a topoisomerase inhibitor, which potentially induces cytotoxicity in TF-expressing tumor cells and inhibits tumor growth (Cancer Res (2025) 85 (8_Supplement_1): 2936). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| XB371 | XB-371|XB 371 | XB371 is an antibody-drug conjugate (ADC) comprising a monoclonal antibody targeting tissue factor (TF) linked to a topoisomerase inhibitor, which potentially induces cytotoxicity in TF-expressing tumor cells and inhibits tumor growth (Cancer Res (2025) 85 (8_Supplement_1): 2936). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07123103 | Phase I | XB371 | A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | 0 |